



Past, Present, and Future Strategies in the Treatment and Management of Gliomas

Guest Editor:

Prof. Dr. Alfredo Conti

1. Unit of Neurosurgery, IRCCS
Istituto delle Scienze
Neurologiche di Bologna, 40139
Bologna, Italy
2. Department of Biomedical and
Neuromotor Sciences, Alma
Mater University of Bologna,
Bologna, Italy

Deadline for manuscript
submissions:

closed (15 May 2024)

Message from the Guest Editor

Dear Colleagues,

Gliomas are the most common primary malignant brain tumors, according to the World Health Organization (WHO) histological grading, gliomas are classified into two main categories, namely low-grade gliomas and high-grade gliomas.

Undoubtedly, gliomas of all grades continue to represent an incurable life-limiting disease and an unmet clinical need to improve under several points of view. Improvement of our current knowledge of tumor biology and potential therapeutic targets, identification of biomarkers to detect patients who are at risk of earlier recurrence or more aggressive clinical course, new surgical techniques to achieve safer and more radical surgical resection, innovative radiotherapy and nuclear medicine approaches are all fields that need deeper investigation.

This Special Issue aims to gather groundbreaking research articles and updated reviews from experts in the fields of basic, translational, and clinical research of glioma. Emphasis will be placed on recent therapeutic advancements, but even cutting-edge research in tumor biology, biomarkers, and imaging will be welcome to complement this dedicated Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)